ホーム 計算ツール
代理店ログイン

検索結果

Search Results for " Linker for Activation of B-Cells "

6

リコンビナントタンパク質

Recombinant Proteins

カタログ番号 製品名 Species Expression System
TMPJ-01323 NTAL Protein, Human, Recombinant (His) Human HEK293 Cells
Linker for Activation of T-Cells Family Member 2 (LAT2) is a single-pass type III membrane protein. LAT2 is highly expressed in the spleen, peripheral blood lymphocytes, and germinal centers of lymph nodes. LAT2 is invol...
TMPH-02271 BTK Protein, Human, Recombinant (His) Human Baculovirus Insect Cells
Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activatio...
TMPY-02191 BLNK Protein, Human, Recombinant (His) Human HEK293 Cells
B-cell linker protein, also known as B-cell adapter containing a SH2 domain protein, B-cell adapter containing a Src homology 2 domain protein, Cytoplasmic adapter protein, Src homology 2 domain-containing leukocyte p...
TMPK-01413 H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi) Mouse HEK293 Cells
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of...
TMPK-01416 HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated Human HEK293 Cells
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 we...
TMPK-01412 HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi) Human HEK293 Cells
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 we...